Sandoz Canada announces that Health Canada has provided authorization to market Jubbonti. “Denosumab is an important biologic therapy used by more than 500,000 patients in Canada. As a pioneer in patient access, we take great pride in being the first company to introduce and bring to the Canadian market a denosumab biosimilar in the field of immunology.” – Michel Robidoux, President and General Manager, Sandoz Canada
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SDZNY: